PGT-A, costly and unreliable yet marketed vigorously [PR]
Posted on Jan 11, 2021
Dr. Gleicher joins two prominent colleagues in warning against the widespread utilization of PGT-A, in an opinion paper just published in Trends in Molecular Medicine. Learn more in our press release here.
Norbert Gleicher, MD, FACOG, FACS
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.
We have helped women bring over 17,800 babies into the world.
Discover your treatment optionsRelated Articles
- What is new regarding COVID-19? Most of the COVID-19 news these days is positive: new infections in the U.S. and countries, like Israel, have been declining rapidly and, with its deaths from the disease. At the same time, the news in big parts of the world, especially Europe and Brazil, is not that favorable.
- Breaking News in ScienceLetter to President Biden and Secretary Designate of HHS, Xavier Becerra In a published letter (Santoro et al Reprod Sciences 2021; https:/doi.org/10.1007/s43032-021-00491-9), a
- More On COVID-19DOES THE BRITISH STRAIN B.1.1.7 INCREASE MORTALITY OVER D614G? A just published study by British investigators claims that not only infectivity of the
- February CHR VOICE DigestBased on feedback from our readers, each month we will be highlighting what we consider the most important news for